



## **Idera Pharmaceuticals to Announce Third Quarter 2014 Financial Results and Corporate Update on November 7, 2014**

October 29, 2014 8:30 PM EDT

CAMBRIDGE, Mass., Oct. 29, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical stage biopharmaceutical company developing nucleic acid therapeutics for patients with rare diseases, today announced that the Company will host a conference call and live audio webcast at 8:00 a.m. EST on Friday, November 7, 2014 to report its third quarter 2014 financial results and provide an update on recent business activities.

The live webcast can be accessed under "Investor Events" in the Investors and Media section of the Company's website at [www.iderapharma.com](http://www.iderapharma.com). To access the conference call, dial 1-866-202-0886 (domestic) or 1-617-213-8841 (international) and provide the access code 74052148. Following the event, an archive of the webcast will be available on the Company's website for 90 days.

### **About Idera Pharmaceuticals**

Idera Pharmaceuticals is a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of genetically defined forms of B-cell lymphoma and rare autoimmune diseases. Idera's proprietary technology involves creating novel nucleic acid therapeutics designed to inhibit over-activation of Toll-like receptors (TLRs). In addition to its TLR programs, Idera is developing gene silencing oligonucleotides (GSOs) that it has created using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit [www.iderapharma.com](http://www.iderapharma.com).

CONTACT: Jim Baker  
Executive Director, Corporate Affairs  
617-679-5516 [  
[jbaker@iderapharma.com](mailto:jbaker@iderapharma.com)

[Idera Pharmaceuticals Logo](#)

**Idera Pharmaceuticals**